T-cell receptor (TCR)

The T-cell receptor is a membrane-bound heterodimeric protein complex found exclusively on the surface of mature T lymphocytes. It is composed most commonly of an alpha chain and a beta chain linked by disulfide bonds; a minority population expresses gamma-delta chains instead. Each chain contains variable and constant domains structurally related to those found in antibodies. The variable regions together form a single antigen-binding site per molecule. The primary function of the T-cell receptor is highly specific recognition of peptide fragments presented by major histocompatibility complex (MHC) molecules on other cells—a process central to adaptive immunity. Upon binding its cognate peptide-MHC ligand, conformational changes trigger intracellular signaling through associated invariant proteins known as CD3 subunits and zeta chains; these contain ITAM motifs essential for signal transduction leading ultimately to full activation, proliferation, differentiation, or effector functions such as cytotoxicity. The diversity required for broad antigen recognition arises from somatic recombination during thymocyte development—analogous but distinct from antibody gene rearrangement—resulting in an enormous repertoire capable collectively recognizing virtually any foreign peptide. Because it orchestrates key steps in immune surveillance against infection and cancer—and can contribute pathologically when misdirected—the T-cell receptor is both an essential physiological mediator and an important therapeutic target across oncology, infectious diseases, autoimmunity, transplantation medicine, and beyond

Other names

TCRT cell antigen receptorαβ T-cell receptor (for the most common form)γδ T-cell receptor (for the less common form)

Drugs and biologics that interact with or modulate the function of the T-cell receptor typically act by one or more of these mechanisms: – Redirecting cytotoxicity by engaging both tumor antigens and CD3/TCR on effector cells (“bispecific” mechanism) – Genetically engineering patient’s own lymphocytes to express a specific tumor-antigen recognizing TCR (“adoptive transfer” mechanism) – Modulating downstream signaling pathways following antigen engagement